Molecular structure of Fmoc-tranexamic acid, CAS Number: 167690-53-1
Fmoc-tranexamic acid (CAS 167690-53-1)
Alternate Names:
Trans-4-(Fmoc-aminomethyl)cyclohexanecarboxylic acid
CAS Number:
167690-53-1
Purity:
≥99%
Molecular Weight:
379.45
Molecular Formula:
C23H25NO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Fmoc-tranexamic acid is a synthetically produced organic compound with potential applications in areas such as biochemistry and scientific research. Originating from fluorene, a polyaromatic hydrocarbon (PAH) present in coal tar, Fmoc-tranexamic acid exhibits a broad spectrum of biological activities. Researchers have investigated its capability to inhibit enzymes and to modulate gene expression. The inhibition of enzymes is thought to occur when it binds to the enzyme, thus halting its ability to catalyze a reaction, which can impact a variety of metabolic pathways, including those associated with cell growth. The modulation of gene expression is speculated to occur when Fmoc-tranexamic acid binds to DNA, resulting in the alteration of specific gene expressions, which can subsequently lead to changes in the expression of proteins involved in cell growth and development.
Fmoc-tranexamic acid (CAS 167690-53-1) References
- Design, synthesis, screening, and decoding of encoded one-bead one-compound peptidomimetic and small molecule combinatorial libraries. | Liu, R., et al. 2003. Methods Enzymol. 369: 271-87. PMID: 14722959
- Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins. | Sosic, A., et al. 2018. Bioconjug Chem. 29: 2195-2207. PMID: 29791798
- Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes. | Kuo, HT., et al. 2018. Mol Pharm. 15: 3502-3511. PMID: 29920108
- Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies. | Kuo, HT., et al. 2018. Mol Pharm. 15: 5183-5191. PMID: 30251544
- Design, Synthesis, and Characterization of Macrocyclic Inhibitors of the Proprotein Convertase Furin. | Van Lam van, T., et al. 2019. ChemMedChem. 14: 673-685. PMID: 30680958
- Functionally Versatile and Highly Stable Chelator for 111In and 177Lu: Proof-of-Principle Prostate-Specific Membrane Antigen Targeting. | Li, L., et al. 2019. Bioconjug Chem. 30: 1539-1553. PMID: 31009566
- tBu4octapa-alkyl-NHS for metalloradiopeptide preparation. | Li, L., et al. 2020. Dalton Trans. 49: 7605-7619. PMID: 32459231
- Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics. | Bendre, S., et al. 2020. Molecules. 25: PMID: 32854201
- The Importance of Linkers in the Structure of PSMA Ligands. | Uspenskaya, AA., et al. 2022. Curr Med Chem. 29: 268-298. PMID: 34348608
- Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone. | Hirata, S., et al. 2022. Nucl Med Biol. 114-115: 34-41. PMID: 36088875
- Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers. | Murce, E., et al. 2023. R Soc Open Sci. 10: 220950. PMID: 36908985
- Synthesis and biological evaluation of diagnostic reagent for prostate cancer using copper-64 radioisotope | Ahn, Heesu (Division of Applied RI, Korea Institute of Radiological and Medical Sciences); Kim, Mi Hyun (FutureChem Healthcare Co., Ltd.); Han, Sang Jin (Division of Applied RI, Korea Institute of Radiological and Medical Sciences); Woo, Sang Keun (Division of Applied RI, Korea Institute of Radiological and Medical Sciences); Kim, Jung Young (Division of Applied RI, Korea Institute of Radiological and Medical Sciences); Lee, Kyu Chul (Division of Applied RI, Korea Institute of Radiological and Medical Sciences); Lim, Il Han (Division of Applied RI, Korea Institute of Radiological and Medical Sciences); Lee, Yong Jin (Division of Applied RI, Korea Institute of Radiological and Medical Sciences). 2018. Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지). Volume 4 Issue 2 /: Pages.65-72.
- A novel stereospecific PSMA-targeting pharmacophore with reduced kidney and salivary gland accumulation in a murine model of human prostate cancer | Hsiou-Ting Kuo, Zhengxing Zhang, Chengcheng Zhang, Helen Merkens, Kuo-Shyan Lin and Francois Benard. June 1, 2022. Journal of Nuclear Medicine. Vol. 63, Issue supplement 2: 2476.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fmoc-tranexamic acid, 1 g | sc-285841 | 1 g | $68.00 | |||
Fmoc-tranexamic acid, 5 g | sc-285841A | 5 g | $250.00 |